

From: Jennifer Wellman  
To: Glen, Jacqueline  
Cc: Morris, Nevitt; Paul Gil  
Subject: Re: Information request for BLA 126610  
Date: Saturday, June 03, 2017 1:30:30 PM  
Attachments: image001.png

image002.png

(File Attachment comment)

(File Attachment comment)

Dear Ms. Glen,

I acknowledge receipt of this email and have included my colleague, Paul Gil, Ph.D., Regulatory CMC Lead, on this reply. Thank you, Jennifer

Jennifer A. Wellman

Co-Founder and Head of Product Development Strategy  
Spark Therapeutics, Inc.  
3737 Market Street, Suite 1300  
Philadelphia, PA 19104

Jennifer.Wellman@sparktx.com

Mobile: 267-971-9177

Office: 215-220-9334

www.sparktx.com

From: "Glen, Jacqueline" <Jacqueline.Glen@fda.hhs.gov>  
Date: Friday, June 2, 2017 at 4:40 PM  
To: Jennifer Wellman <Jennifer.Wellman@sparktx.com>  
Cc: "Morris, Nevitt" <Nevitt.Morris@fda.hhs.gov>  
Subject: Information request for BLA 126610

Dear Ms. Wellman:

Please provide a response to the information requested by June 9, 2017.

CMC Information Request (June 1, 2017):

1.

In your submission of "2.3.S Quality Overall Summary" Table 8 "AAV2 Manufacturing Lots Included in Process Database used for Development of Interim Control Strategy", you listed 9 lots manufactured at CHOP and 4 lots

manufactured at Spark. Please provide a chart including the following information for each lot listed in the Table 8:

a.

Date manufactured and released

b.

Lot scale

c.

Purpose and the usage of each lot such as:

(Unsigned signature field (Click to sign)) Signature field is unsigned

i.

Clinical use

ii.

Manufacturing process development and qualification

iii. Comparability study

iv. Stability study

v.

Generate the testing specifications for lot release or for comparability studies

2.

Please provide a summary table including all of the lot release testing results for

the product lots listed in your Table 8 "AAV2 Manufacturing Lots Included in

Process Database used for Development of Interim Control Strategy".

Please

include all available testing results of drug substances and drug products.

3.

Please provide detailed facility information for the "Secondary Packaging" for

your final product (one vial of Drug Product is co-packaged with two vials

Diluent). Please provide the detailed information for the packaging facility and

process qualification for the "Secondary Packaging". Please include the shipping

conditions and validation reports, including, storage conditions and package

labeling process qualification information.

4.

Please clarify whether your Drug Product vial and Diluent vial will be labeled at

(b) (4) or at the "Secondary Packaging" facility. Please provide the detailed

procedures for labeling the vials, packages, boxes, and for the shipping.

5.

Regarding the delivery devices listed in your "Surgical Training Manual for the

Administration of LUXTURNA". Please clarify if any of the listed in Tables 1, 2,

and 3 devices (i.e., cannulas, extension tubes, and syringes) are 510(k)-cleared

or exempt. Please provide the 510(k) numbers for those devices if applicable.

6.

Please provide data that supports compatibility of the product (Luxturna) with

all delivery device components (e.g., cannulas, syringes and extension tubes)

that are listed in the "Surgical Training Manual", and that will be in contact

with the product during formulation in the pharmacy and during subretinal administration in the patient.

The BLA submission contains two Biocompatibility Reports in Section 3.2R that contain data to support compatibility of the product with the delivery system (Study Report TR2016-046 and Study Report TR2016-049). However, we note that the following device components listed in the "Surgical Training Manual" are not covered by either study report:

- 1). Cannula: Retinal hydrodissection cannula 20 g/39 g (Storz Ophthalmic - Bausch & Lomb)
- 2). Syringe: Medallion® 1-mL syringe (Merit Medical Systems, Inc)

Please provide the missing information/data to support product compatibility with all device components.

If you have any questions, please contact Nevitt Morris at 240-402-8269 or [Nevitt.Morris@fda.hhs.gov](mailto:Nevitt.Morris@fda.hhs.gov).

Thank you  
Jackie

Jacqueline Glen, MS  
Regulatory Project Manager  
Division of Regulatory Management  
Office of Tissues and Advanced Therapies (OTAT)  
CBER/FDA/HHS

Jacqueline.glen@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."

This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual(s) or entity(ies) named in the e-mail address. If you are not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail is strictly prohibited. If you have received this e-mail transmission in error, please notify the sender immediately, and then please delete the message from your system.